Lenvervimab clinical trials
Also written GC1102.
How each study uses lenvervimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2015 | 2 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses lenvervimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102Status unknownPhase 2/3Green Cross CorporationNCT03519113Written as GC1102 80,000 IU
- A Study of GC1102(Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B PatientsStatus unknownPhase 2Green Cross CorporationNCT03801798Written as GC1102
- A Phase 1 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B PatientsCompletedPhase 1Green Cross CorporationNCT02569372Written as GC1102
- A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant RecipientsCompletedPhase 2Green Cross CorporationNCT02304315Written as GC1102 50,000 IU
- Safety and Pharmacokinetics Study of Healthy Male Adults When Repeatedly Administered Through Intravenous InjectionCompletedPhase 1Green Cross CorporationNCT01606163Written as GC1102
Codes
What other systems call lenvervimab · ClinicalTrials.gg INT016605
- UNII (FDA) FX9X4L2A2LLENVERVIMABOne source FDA
- NCI Thesaurus C170106LenvervimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FX9X4L2A2L | LENVERVIMAB | One source FDA |
| NCI Thesaurus | C170106 | Lenvervimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.